Search

membership

Organisation type

Index

BioPartner UK

BioPartner UK is your point of contact for the UK delegation to Cologne. Visit us in the Exhibition Hall to find out more about doing business with UK companies, and to meet those in the UK delegation.

Biopartner UK leads the UK Delegation to several partnering conferences each year. It is a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK. BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.

Biopartner has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.

Lin Bateson

Executive Director

Alasdair Stamps

Chairman

Miss Caroline Wright

Exhibition Assistant

Mr Luke Lloyd

Marketing Communications Executive

Biotech and Money

Biotech and Money is a growing influential community of senior life science decision makers. We are a catalyst for dialogue, debate and deal making to help lead growth in healthcare investment and the building of billion dollar healthcare businesses.

We are determined to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare.

Mr Matt Pullan

Senior Vice President

CAMBRIDGE RESEARCH BIOCHEMICALS

Our core business is the chemical synthesis of peptides and the custom production of polyclonal antibodies.

Peptides and antibodies are different forms of proteins. As proteins control every process essential for life, discovering more about how they work and how they help the body fight disease and infection, is crucial for furthering medical research, drug development and health care provision.

All CRB’s products are used purely for medical research purposes — primarily drug discovery and disease research — either by commercial organisations or academic institutes. We do not sell them to be used directly on patients.

Alongside this custom-production, we also ‘partner’ small, highly specialised biochemical businesses to help them promote their services and gain wider exposure.

Dr SOPHIE ROSE

MARKETING MANAGER AND PRODUCT SPECIALIST

Canbex Therapeutics Ltd

Canbex Therapeutics is dedicated to treating spasticity in multiple sclerosis (MS) and other disorders. Spasticity is a debilitating and painful symptom that consists of involuntary spasms and stiffness of limbs and torso. The goal of the Canbex lead programme is to improve the lives of people with this serious and incurable disorder, and set a new standard in the treatment of spasticity.

The company’s lead compound, VSN16R, is currently in a Phase II study to determine its efficacy in relieving spasticity in people with MS. VSN16R was shown to be safe and well tolerated in a Phase I human safety trial in healthy volunteers that was completed in 2014.

Dr Keith Powell

Chairman

Dr Jesse Schulman

CEO

Cell and Gene Therapy Catapult

The Cell Therapy Catapult was established in 2012 as a centre of excellence in innovation, with the core purpose of building a world-leading cell therapy industry in the UK. Supported by Innovate UK, our mission is to drive the growth of the industry by helping cell therapy organisations across the world translate early stage research into commercially viable and investable therapies.

Censo Biotechnologies Ltd

The company has the capabilities to generate induced pluripotent stem cells (iPSCs) from large cohorts of individuals and use the potential of these cells to create virtually any cell in the human body.

By developing cell-based models of disease using cells from a diverse range of tissue donors, the company supports the development of new targeted treatments for disease. Its major focus is the generation of novel data on drug efficacy and drug response variation for a given population.

Mr Aidan Courtney

Chief Executive Officer

Dr Julie Holder

Head of Innovation

CIMYM BioSciences

CIMYM BioSciences was established to develop oncology and immunological therapeutics. At CIMYM we believe passionately that drug development can only be successful if it is patient centred…’Begin with the patient in mind'. As a healthcare company we recognise an exceptional idea to fill a medical need, build a network and then establish a clinical utility that will improve patient care. CIMYM uses its expertise to manage value-enhancing activities in the development process of pharmaceuticals and diagnostics. It takes a patient-centred approach to co-develop these innovative products and in turn licenses the rights for manufacture and marketing to other pharmaceutical companies.

CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team.

BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.

With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies.

CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/regulatory approach to ensure value is strategically added at every stage of the product development life cycle.

Further information about CNS and its intelligent development services can be found at www.clinical.net.au

Paul Cronin

Director of Business Development

Russell Neal

Managing Director

Dr Andrew Carnegie

Business Development Manager

Crescendo Biologics Ltd

Crescendo has developed a novel antibody fragment platform which generates fully human VH products, the smallest antibody fragments, that mature in vivo in a transgenic mouse. The company has a highly experienced antibody drug discovery team and capability. Crescendo is using the platform to develop a portfolio of differentiated medicines, with an initial focus on novel topical products, and is identifying companies interested in partnering this platform.

Dr Nigel Crockett

Head Business Development

Dr Peter Pack

CEO

Crystec Limited

Crystec applies the latest supercritical fluid (SCF) technology to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical and biopharmaceutical industries, contributing to human health by enabling new and more effective therapies. Crystec SCF technology can be applied to small and large drug molecules in a range of dosage forms. Our expertise includes designing the world’s first SCF engineered drug (Semprana – inhaled delivery for migraine), which is expected to launch later this year.

Our services include crystal form screening and particle design (including composite particles and scalable co-crystals), addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management. Our process is scaled to GMP manufacturing levels.

We also have a strong product pipeline, focused on repurposing existing therapies. These assets are in a number of therapeutic areas including urge incontinence, women’s health, fungal infections, and malaria, and are currently available for out-licensing.

For more information on our technology or assets please visit www.crystecpharma.com or contact Catherine Hunter, Business Development Director (catherine.hunter@cystecpharma.com).